ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML

Autor:	Mario Tiribelli, Antonella Geromin, Renato Fanin, Erica Simeone, Margherita Cavallin, Daniela Damiani, Sara Di Giusto
Rok vydání:	2017
Předmět:	Adult Male Oncology medicine.medical_specialty NPM1 Adolescent Abcg2 ABCG2 Gene Expression favorable risk acute myeloid leukemia Biology Young Adult 03 medical and health sciences 0302 clinical medicine Molecular classification Antigens CD Recurrence Internal medicine medicine Overall survival ATP Binding Cassette Transporter Subfamily G Member 2 Humans In patient Relapse risk Aged CD200 prognosis Hematology Complete remission Myeloid leukemia General Medicine Middle Aged Survival Analysis Neoplasm Proteins Leukemia Myeloid Acute fms-Like Tyrosine Kinase 3 030220 oncology & carcinogenesis Cytogenetic Analysis Mutation embryonic structures Cancer research biology.protein Female sense organs Nucleophosmin Biomarkers 030215 immunology
Zdroj:	European Journal of Haematology. 99:269-274
ISSN:	0902-4441
Popis:	Objective overexpression of ABCG2 and CD200 have been independently associated with poor outcome in acute myeloid leukemia (AML). However, no data are available on the role of these two factors in patients with core binding factor (CBF) positive or FLT3-negative / NPM1-mutated cytogenetically normal (CN) AML. Methods we analyzed 65 adult AML patients with CBF+ (n=16) or FLT3-/NPM1+ CN (n=49), evaluating clinical and biological factors associated with complete remission attainment, leukemia-free survival (LFS) and overall survival (OS). Results ABCG2 was expressed in 36 (55%) cases, and CD200 was positive in 33 (51%) cases, 6 at high levels. Both ABCG2 or CD200 positivity have a negative impact on relapse risk: 3-year LFS was 51% vs 82% in ABCG2+ cases (RR 3.3), 49% vs 82% in CD200+ patients (RR = 4.4) and 25% in CD200-high cases (RR = 17.1). ABCG2 and CD200 affected also OS with 3-year OS of 39% in ABCG2+ (compared to 71% in ABCG2-; RR = 2.6) and CD200+ (compared to 68% in CD200-; RR = 2.5) patients. Conclusion our data confirm a negative impact of ABCG2 and CD200 overexpression also in AML patients considered at favorable risk according to ELN cytogenetic/molecular classification. This article is protected by copyright. All rights reserved.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63d0b6128cfd20f2c7ac66a65603a159 https://doi.org/10.1111/ejh.12915 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.